RGEN
Repligen Corporation Common Stock
Healthcare · Medical Instruments & Supplies · NASDAQ · United States
$186.75+3.34%
Market cap $10.2BNext earnings 2026-10-27Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$186.75+0.0%
confidence-weighted across 4 of 6 models
Now $186.75
$186.75
$23.55$48.23
AvoidBronze51
Price vs fair value
512.3% above
-83.7% to fair value
ACCE score
52
out of 100
Analysts
74% buy
19 covering
P/E
247.5x
forward 64.5x
1-year return
+48.3%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOROverview
Reports in 33 days, last quarter beat by 0.2%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
+50.7% · 1Y
Valuation
INVESTORFull valuation engine INVESTOR FEATURE
Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORQuality and conviction INVESTOR FEATURE
The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
Bullish74% buy · 19 covering analysts
● Strong buy 10● Buy 4● Hold 5● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROSmart money tracking PRO FEATURE
Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x247.5xhigh 247.5x
ROEbetter than 33% of peers
low -14%2%high 19%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 5.5%
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| AVTR | Avantor Inc. Common Stock | $10.2B | - | -9.7% | 0.71 | 0.0% | - | Compare |
| COO | The Cooper Companies Inc. Common Stock | $10.3B | 18.6 | 6.8% | 0.30 | 0.0% | - | Compare |
| ALGN | Align Technology Inc. Common Stock | $10.4B | 25.5 | 10.2% | 0.01 | 0.0% | - | Compare |
| BAX | Baxter International Inc. Common Stock | $11.9B | - | -14.4% | 1.55 | 0.9% | - | Compare |
| ATR | AptarGroup Inc. Common Stock | $7.8B | 22.3 | 13.5% | 0.56 | 1.5% | - | Compare |
| COLO-B.CO | Coloplast A/S | $14.6B | 34.4 | 18.5% | 1.36 | 5.5% | - | Compare |
Sector report card
Where RGEN ranks against its sector peers on each metric.
Computing percentiles…
News and Record
Reports in 33 days, last quarter beat by 0.2%.
Press releases mentioning this company
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.
PRO
Recent performance
1 week
+6.9%
1 month
+3.1%
3 months
+34.9%
6 months
+63.2%
YTD
+14.0%
1 year
+48.3%
SEC filings
40 filings
September 2026
Sep 15
8-KCurrent reportPeriod 2026-09-10
Sep 8
8-KCurrent reportPeriod 2026-09-03
Sep 8
Form 4Insider transactionPeriod 2026-09-03
37 more filings + AI summaries on Investor+.INVESTOR